Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024
April 01, 2024 at 03:07 am EDT
Share
Torrent Pharmaceuticals Limited announced that Shailesh Haribhakti (DIN: 00007347) and Haigreve Khaitan (DIN: 00005290) have completed their tenure as Independent Directors of the Company on 31-March 2024, pursuant to which they ceased to be the Directors of the Company. Sudhir Mehta (DIN: 00061871) has stepped down as Director of the Company effective 31-March 2024. He will continue to be Chairman Emeritus. Shailesh Haribhakti has completed his tenure as an Independent Director of the Company on 31st March, 2024, pursuant to which he ceased to be the Director of the company Haigreve Khaitan has completed his tenure as an Independent Director of the Company on 31st March, 2024, pursuant to which he ceased to be the Director of the company Sudhir Mehta has stepped down as Director of the Company effective 31st March, 2024. He will
continue to be Chairman Emeritus.
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
TORRENT PHARMACEUTICALS LIMITED 
